Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × Drug Therapy × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 47 Breast Neoplasms 22 Lung Neoplasms 18 Pancreatic Neoplasms 15 Neoplasm Metastasis 15 Neoplasms 13 Colorectal Neoplasms 13 Triple Negative Breast Neoplasms 12 Stomach Neoplasms 11 Head and Neck Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 9 Small Cell Lung Carcinoma 9 Rectal Neoplasms 9 Esophageal Squamous Cell Carcinoma 9 Uterine Cervical Neoplasms 8 Esophageal Neoplasms 8 Ovarian Neoplasms 7 Leukemia, Myeloid, Acute 6 Cholangiocarcinoma 6 Urinary Bladder Neoplasms 5 Recurrence 5 Fallopian Tube Neoplasms 5 Sarcoma 4 NSCLC 4 Lymphoma 4 Glioblastoma 4 Colonic Neoplasms 4 Carcinoma, Squamous Cell 4 Prostatic Neoplasms 3 Oropharyngeal Neoplasms 3

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06731140 2025-11-17

Resilire

Fudan University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡